Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy

NCT07678931 is registered in ClinicalTrials.gov with Chengdu Kangnuoxing Biopharma,Inc. as lead sponsor.

NCT NCT07678931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07678931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy
Lead sponsor
Chengdu Kangnuoxing Biopharma,Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 13, 2026
Completion date
December 31, 2026
Enrollment
136 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic rhinitis (sar)